CEFROXADINE DIHYDRATE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C16H19N3O5S.2H2O
Molecular Weight	401.435
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O.O.COC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)C3=CCC=CC3)C2=O)C(O)=O

InChI

InChIKey=WDYHZZPITKKPTD-OEDJVVDHSA-N

InChI=1S/C16H19N3O5S.2H2O/c1-24-9-7-25-15-11(14(21)19(15)12(9)16(22)23)18-13(20)10(17)8-5-3-2-4-6-8;;/h2-3,6,10-11,15H,4-5,7,17H2,1H3,(H,18,20)(H,22,23);2*1H2/t10-,11-,15-;;/m1../s1

HIDE SMILES / InChI

Molecular Formula	C16H19N3O5S
Molecular Weight	365.404
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	3 / 3
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	H2O
Molecular Weight	18.0153
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.ncbi.nlm.nih.gov/pubmed/6998373

Cefroxadine is an antibiotic developed for the treatment of bacterial infectious diseases caused by gram-negative and gram-positive organisms. The information about drug status is unavailable and is supposed to be "discontinued", however it may be manufactured in Italy by Novartis.

Originator

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
Bacterial infections 235 Sources: http://www.ncbi.nlm.nih.gov/pubmed/6998373	Curative		Approved 8583	ORASPOR Approved Use Unknown

C_max

Value	Dose	Analyte	Population
17.62 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16137854/	500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered:	CEFROXADINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
4.5 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7389422/	125 mg single, oral dose: 125 mg route of administration: Oral experiment type: SINGLE co-administered:	CEFROXADINE serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
7.7 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7389422/	250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered:	CEFROXADINE serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
12.3 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7389422/	500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered:	CEFROXADINE serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
7.6 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7069577/	212 mg single, oral dose: 212 mg route of administration: Oral experiment type: SINGLE co-administered:	CEFROXADINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
16 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7069577/	424 mg single, oral dose: 424 mg route of administration: Oral experiment type: SINGLE co-administered:	CEFROXADINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
28.8 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7069577/	847 mg single, oral dose: 847 mg route of administration: Oral experiment type: SINGLE co-administered:	CEFROXADINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
46.25 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16137854/	500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered:	CEFROXADINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
6.1 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7389422/	125 mg single, oral dose: 125 mg route of administration: Oral experiment type: SINGLE co-administered:	CEFROXADINE serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
12.07 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7389422/	250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered:	CEFROXADINE serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
23.59 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7389422/	500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered:	CEFROXADINE serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
2.55 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7069577/	50 mg single, intravenous dose: 50 mg route of administration: Intravenous experiment type: SINGLE co-administered:	CEFROXADINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
10.1 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7069577/	212 mg single, oral dose: 212 mg route of administration: Oral experiment type: SINGLE co-administered:	CEFROXADINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
21.3 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7069577/	424 mg single, oral dose: 424 mg route of administration: Oral experiment type: SINGLE co-administered:	CEFROXADINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
44.4 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7069577/	847 mg single, oral dose: 847 mg route of administration: Oral experiment type: SINGLE co-administered:	CEFROXADINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16137854/	500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered:	CEFROXADINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
1.13 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7389422/	125 mg single, oral dose: 125 mg route of administration: Oral experiment type: SINGLE co-administered:	CEFROXADINE serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
0.85 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7389422/	250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered:	CEFROXADINE serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
0.92 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7389422/	500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered:	CEFROXADINE serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
0.74 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7069577/	50 mg single, intravenous dose: 50 mg route of administration: Intravenous experiment type: SINGLE co-administered:	CEFROXADINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
1.03 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7069577/	212 mg single, oral dose: 212 mg route of administration: Oral experiment type: SINGLE co-administered:	CEFROXADINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1.03 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7069577/	424 mg single, oral dose: 424 mg route of administration: Oral experiment type: SINGLE co-administered:	CEFROXADINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1.03 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7069577/	847 mg single, oral dose: 847 mg route of administration: Oral experiment type: SINGLE co-administered:	CEFROXADINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

Doses

Dose	Population	Adverse events
40 mg/kg 4 times / day multiple, oral Studied dose Dose: 40 mg/kg, 4 times / day Route: oral Route: multiple Dose: 40 mg/kg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7334585	unhealthy, CHILD Health Status: unhealthy Age Group: CHILD Sex: unknown Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/7334585	Other AEs: Diarrhea... Other AEs: Diarrhea (mild, 3 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/7334585
250 mg 4 times / day multiple, oral Studied dose Dose: 250 mg, 4 times / day Route: oral Route: multiple Dose: 250 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6436182/	unhealthy Health Status: unhealthy Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/6436182/	Disc. AE: Oedema... Other AEs: Diarrhoea... AEs leading to discontinuation/dose reduction: Oedema (1 pt) Other AEs: Diarrhoea (2 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/6436182/

AEs

AE	Significance	Dose	Population
Diarrhea	mild, 3 patients	40 mg/kg 4 times / day multiple, oral Studied dose Dose: 40 mg/kg, 4 times / day Route: oral Route: multiple Dose: 40 mg/kg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7334585	unhealthy, CHILD Health Status: unhealthy Age Group: CHILD Sex: unknown Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/7334585
Oedema	1 pt Disc. AE	250 mg 4 times / day multiple, oral Studied dose Dose: 250 mg, 4 times / day Route: oral Route: multiple Dose: 250 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6436182/	unhealthy Health Status: unhealthy Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/6436182/
Diarrhoea	2 patients	250 mg 4 times / day multiple, oral Studied dose Dose: 250 mg, 4 times / day Route: oral Route: multiple Dose: 250 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6436182/	unhealthy Health Status: unhealthy Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/6436182/

PubMed

Title	Date	PubMed
A specific and rapid HPLC assay for the determination of cefroxadine in human plasma and its application to pharmacokinetic study in Korean.	2006-02-13	16137854
[Antibacterial activity of oral cephems against various clinically isolated strains and evaluation of efficacy based on the pharmacokinetics/pharmacodynamics theory].	2004-12	15747584

Patents

Sample Use Guides

In Vivo Use Guide

The daily dosage of 1000mg should be divided into 2 fractions and should be taken after breakfast and after supper.

Route of Administration: Oral

In Vitro Use Guide

The spectrum of antibacterial activity of cefroxadine against gram-positive and gram-negative bacteria was studied. About 0.005 ml of diluted culture was inoculated by Micro-planter onto agar plates containing a series of serial twofold dilutions of a drug. The concentration of the drug required to inhibit the growth of 50% of the total number of tested E. coli strains (MIC50) was 3.13 to 6.25 ug/ml. The MIC50 of cefroxadine against K. pneumoniae strains was 3.13 to 6.25 ug/ml.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 21:33:29 GMT 2025` Edited by `admin` on `Mon Mar 31 21:33:29 GMT 2025`
Record UNII	439L36E61V
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID, 7-((AMINO-1,4-CYCLOHEXADIEN-1-YLACETYL)AMINO)-3-METHOXY-8-OXO-, DIHYDRATE, (6R-(6.ALPHA.,7.BETA.(R*)))-

Preferred Name

English

CEFROXADINE DIHYDRATE

Common Name

English

CEFROXADINE DIHYDRATE [MI]

Common Name

English

CEFROXADINE HYDRATE [JAN]

Common Name

English

Cefroxadine hydrate [WHO-DD]

Common Name

English

Code System Code Type Description

FDA UNII

439L36E61V